These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 37653627)
1. Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance. Zheng C; Guo H; Mo Y; Liu G Recent Pat Anticancer Drug Discov; 2024; 19(5):681-694. PubMed ID: 37653627 [TBL] [Abstract][Full Text] [Related]
2. Identification and Verification of Necroptosis-Related Gene Signature and Associated Regulatory Axis in Breast Cancer. Hu T; Zhao X; Zhao Y; Cheng J; Xiong J; Lu C Front Genet; 2022; 13():842218. PubMed ID: 35251139 [No Abstract] [Full Text] [Related]
3. Identification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis. Wu Z; Wan J; Wang J; Meng X; Qian H Biochem Biophys Rep; 2022 Mar; 29():101203. PubMed ID: 35059509 [TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analysis and experimental validation of six cuproptosis-associated genes as a prognostic signature of breast cancer. Chen X; Sun H; Yang C; Wang W; Lyu W; Zou K; Zhang F; Dai Z; He X; Dong H PeerJ; 2024; 12():e17419. PubMed ID: 38912044 [TBL] [Abstract][Full Text] [Related]
5. Fatty Acid Metabolism Signature Contributes to the Molecular Diagnosis of a Malignant Gastric Cancer Subtype with Poor Prognosis and Lower Mutation Burden. Chen Z; Cheng G Recent Pat Anticancer Drug Discov; 2024; 19(5):666-680. PubMed ID: 37691229 [TBL] [Abstract][Full Text] [Related]
6. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer. Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036 [TBL] [Abstract][Full Text] [Related]
7. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer. Nie S; Ni N; Chen N; Gong M; Feng E; Liu J; Liu Q J Ovarian Res; 2023 Apr; 16(1):82. PubMed ID: 37095524 [TBL] [Abstract][Full Text] [Related]
8. Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening. Duan W; Chen Y; Shan J; Li Q Recent Pat Anticancer Drug Discov; 2024; 19(5):635-651. PubMed ID: 37877147 [TBL] [Abstract][Full Text] [Related]
9. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
10. Integrated Bioinformatics Analysis to Identify a Novel Four-Gene Prognostic Model of Breast Cancer and Reveal Its Association with Immune Infiltration. Zhu Y; Luo J; Yang Y Crit Rev Immunol; 2024; 44(2):1-14. PubMed ID: 38305332 [TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer. Li C; Zhang Y BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644 [TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients. Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570 [TBL] [Abstract][Full Text] [Related]
13. Integrated Analysis of Circular RNA-Associated ceRNA Network Reveals Potential circRNA Biomarkers in Human Breast Cancer. Sheng H; Pan H; Yao M; Xu L; Lu J; Liu B; Shen J; Shen H Comput Math Methods Med; 2021; 2021():1732176. PubMed ID: 34966440 [TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel necroptosis-related molecular signature to evaluate prognosis and immune features in breast cancer. Zhang F; Qi C; Yao Z; Xu H; Zhou G; Li C; Xia H Apoptosis; 2023 Dec; 28(11-12):1628-1645. PubMed ID: 37787960 [TBL] [Abstract][Full Text] [Related]
15. A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer. Zhang X; Zhang X; Li G; Hao Y; Liu L; Zhang L; Chen Y; Wu J; Wang X; Yang S; Xu S J Immunol Res; 2022; 2022():3143511. PubMed ID: 35578667 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer. Wu Q; Zheng S; Lin N; Xie X BMC Med Genomics; 2023 Apr; 16(1):87. PubMed ID: 37098532 [TBL] [Abstract][Full Text] [Related]
17. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation. Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491 [TBL] [Abstract][Full Text] [Related]
18. Construction of a prognostic model for breast cancer based on moonlighting genes. Zhang M; Zhang D; Wang Q; Lin G Hum Mol Genet; 2024 Jun; 33(12):1023-1035. PubMed ID: 38491801 [TBL] [Abstract][Full Text] [Related]
19. Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer. Chen Y; You Y; Wu Q; Wu J; Lin S; Sun Y; Cui Z Cancer Med; 2023 May; 12(9):11020-11039. PubMed ID: 36951624 [TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a novel prognostic signature based on transcription factors in breast cancer by bioinformatics analysis. Yang Y; Li Z; Zhong Q; Zhao L; Wang Y; Chi H Gland Surg; 2022 May; 11(5):892-912. PubMed ID: 35694087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]